• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis technology highlighted in AJRCCM editorial
Share
Announcements, ProteaseTag®

ProAxsis technology highlighted in AJRCCM editorial

May 17, 2017
-
Posted by Webmaster

ProAxsis Ltd is delighted to observe that its ProteaseTag® Active Neutrophil Elastase Immunoassay is prominently featured in the most recent edition of the American Journal for Respiratory and Critical Care Medicine (AJRCCM). A prospective cohort study led by Dr James Chalmers at the University of Dundee has shown that sputum neutrophil elastase (NE) activity is a biomarker of disease severity and future risk of exacerbation in adults with bronchiectasis. This study involved more than 380 patients with bronchiectasis, who were followed over three years and utilised ProAxsis’ ProteaseTag® Active NE Immunoassay to assess neutrophil elastase activity. The study was previously published online, but has now been included in the May 2017 printed edition of this prestigious journal.

Alongside the article is an editorial authored by Professor Guy Brusselle and Dr Eve Van Braeckel from Ghent University in Belgium. The editors highlight the fact that during the 3-year follow-up, high sputum NE activity was independently associated with future exacerbation rate, hospital admissions and lung function decline. They conclude that Dr Chalmers and colleagues have demonstrated that sputum NE activity is associated not only with clinical and radiological severity of the disease but also with its activity, as evidenced by an increased risk for exacerbations and lung function decline.

Both the article itself and the corresponding editorial, can be accessed on the AJRCCM website. As previously announced, ProAxsis will be presenting further updates on its ProteaseTag® technology at the American Thoracic Society Conference taking place in Washington DC, on May 19th-24th.

Any queries concerning ProAxsis’ Immunoassay for measuring active neutrophil elastase, or any requests for support with measuring other active protease biomarkers using the Company’s proprietary ProteaseTag® technology, can be directed to info@proaxsis.com.

May 17, 2017
No comments yet

Related News

Other posts that you should not miss.
News, ProteaseTag®

ProAxsis receives Royal visit

October 19, 2016
-
Posted by Webmaster

ProAxsis were this week delighted to host His Royal Highness, the Duke of York, at their new laboratory …

Read More
October 19, 2016
Posted by Webmaster
Announcements, News

ProAxsis wins Innovative Business of the Year Award

June 4, 2018
-
Posted by David Ribeiro

ProAxsis Limited has been declared as the “Innovative Business of the Year” at the Business Eye First …

Read More
June 4, 2018
Posted by David Ribeiro
Neutrophil Elastase Immunoassay, News, ProteaseTag®

ProAxsis gains CE Mark for Active Neutrophil Elastase Immunoassay

September 30, 2016
-
Posted by Webmaster

ProAxsis Limited (www.proaxsis.com) is pleased to announce that it has successfully registered a CE Mark for its novel …

Read More
September 30, 2016
Posted by Webmaster
← PREVIOUS POST
ProAxsis CEO to present at Anglonordic Conference
NEXT POST →
ProAxsis successfully licenses additional intellectual property from The Queen’s University of Belfast

Leave a Comment

Your feedback is valuable for us. Your email will not be published.
Cancel Reply

Please wait...
Submit Comment

Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis technology highlighted in AJRCCM editorial - ProAxsis